

Frederic P Clement

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3698099/publications.pdf>

Version: 2024-02-01

33
papers

2,534
citations

279798

23
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

4266
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of the cell-mediated immune response to Takeda's live-attenuated tetravalent dengue vaccine in adolescents participating in a phase 2 randomized controlled trial conducted in a dengue-endemic setting. <i>Vaccine</i> , 2022, 40, 1143-1151.	3.8	9
2	Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults. <i>Frontiers in Immunology</i> , 2018, 9, 564.	4.8	33
3	Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2017, 24, .	3.1	21
4	Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. <i>Scientific Reports</i> , 2017, 7, 8004.	3.3	179
5	Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. <i>Frontiers in Immunology</i> , 2017, 8, 943.	4.8	111
6	A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum. <i>Malaria Journal</i> , 2016, 15, 543.	2.3	10
7	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
8	Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. <i>Cell</i> , 2016, 167, 643-656.e17.	28.9	373
9	Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2211-2219.	3.3	54
10	Processing of blood samples influences PBMC viability and outcome of cell-mediated immune responses in antiretroviral therapy-naïve HIV-1-infected patients. <i>Journal of Immunological Methods</i> , 2014, 414, 1-10.	1.4	19
11	Immunogenicity and Safety of a Booster Dose of an Investigational Adjuvanted Polyprotein HIV-1 Vaccine in Healthy Adults and Effect of Administration of Chloroquine. <i>Vaccine Journal</i> , 2014, 21, 302-311.	3.1	13
12	A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1701-1710.	3.3	31
13	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. <i>PLoS ONE</i> , 2014, 9, e115126.	2.5	26
14	Polyfunctional CD4+ T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine. <i>Vaccine</i> , 2013, 31, 3739-3746.	3.8	34
15	Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial. <i>Vaccine</i> , 2013, 31, 2196-2206.	3.8	135
16	Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1254-1262.	3.3	18
17	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. <i>PLoS ONE</i> , 2013, 8, e55438.	2.5	69
18	Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59® adjuvant. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 216-227.	3.3	32

#	ARTICLE	IF	CITATIONS
19	A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults. <i>Journal of Infectious Diseases</i> , 2012, 206, 1280-1290.	4.0	126
20	Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite <i>Plasmodium falciparum</i> . <i>Malaria Journal</i> , 2012, 11, 384.	2.3	33
21	Vaccine-induced HIV seropositivity: A problem on the rise. <i>Journal of Clinical Virology</i> , 2011, 50, 334-337.	3.1	12
22	H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses. <i>Journal of Clinical Immunology</i> , 2011, 31, 443-454.	3.8	137
23	Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2011, 18, 835-843.	3.1	47
24	An Adjuvanted Polyprotein HIV-1 Vaccine Induces Polyfunctional Cross-Reactive CD4+ T Cell Responses in Seronegative Volunteers. <i>Clinical Infectious Diseases</i> , 2011, 52, 522-531.	5.8	56
25	Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice. <i>Immunology</i> , 2010, 131, 33-39.	4.4	15
26	Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02 Candidate Tuberculosis Vaccine in Purified Protein Derivative-Negative Adults. <i>Vaccine Journal</i> , 2010, 17, 1763-1771.	3.1	49
27	Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. <i>Vaccine</i> , 2010, 28, 7016-7024.	3.8	66
28	Evaluation of Cellular Immunity to Mumps in Vaccinated Individuals with or without Circulating Antibodies up to 16 Years after Their Last Vaccination. <i>Journal of Infectious Diseases</i> , 2009, 199, 1457-1460.	4.0	27
29	Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. <i>Vaccine</i> , 2008, 26, 1375-1386.	3.8	187
30	Vitamin D Binding Protein and the Need for Vitamin D in Hemodialysis Patients. , 2008, 18, 400-407.		10
31	Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. <i>Lancet, The</i> , 2007, 370, 580-589.	13.7	474
32	The duration of in vitro stimulation with recall antigens determines the subset distribution of interferon- γ -producing lymphoid cells: A kinetic analysis using the Interferon- γ Secretion Assay. <i>Journal of Immunological Methods</i> , 2005, 301, 124-139.	1.4	14
33	Evaluation of a New Rapid Test for the Combined Detection of Hepatitis B Virus Surface Antigen and Hepatitis B Virus e Antigen. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4603-4606.	3.9	24